A paliperidone palmitate extended-release injectable suspension having a six month dosing interval (PP6M) for use in a method of stabilizing or decreasing body weight of a patient who has been treated with a paliperidone palmitate extended-release injectable suspension at either one-month intervals (PP1M) or three-month intervals (PP3M), wherein the method comprises administering a last dose of the PP1M or the PP3M and then administering an initial dose of the PP6M, and wherein the patient has a body mass index of about 25 to less than about 30 at the time of the initial dose of the PP6M, wherein the PP6M comprises about 312 mg/mL of paliperidone palmitate; wherein the PP1M comprises about 156 mg/mL of paliperidone palmitate; wherein the PP3M comprises about 312 mg/mL of paliperidone palmitate; wherein the paliperidone palmitate extended-release injectable suspensions are aqueous compositions further comprising a suspending agent, a buffer, and optionally one or more of a preservative and an isotonizing agent, and either A) wherein the initial dose of the PP6M is administered about 1 month (± 7 days) after the last dose of the PP1M is administered, and (Ai) when the last dose of the PP1M comprises about 156 mg of paliperidone palmitate, the initial dose of the PP6M comprises about 1092 mg of paliperidone palmitate, or (Aii) when the last dose of the PP1M comprises about 234 mg of paliperidone palmitate, the initial dose of the PP6M comprises about 1560 mg of paliperidone palmitate, or B) wherein the initial dose of the PP6M is administered about 3 months (± 14 days) after the last dose of the PP3M is administered, and (Bi) when the last dose of the PP3M comprises about 546 mg of paliperidone palmitate, the initial dose of the PP6M comprises about 1092 mg of paliperidone palmitate, or (Bii) when the last dose of the PP3M comprises about 819 mg of paliperidone palmitate, the initial dose of the PP6M comprises about 1560 mg of paliperidone palmitate. wherein the PP6M comprises about 312 mg/mL of paliperidone palmitate; wherein the PP1M comprises about 156 mg/mL of paliperidone palmitate; wherein the PP3M comprises about 312 mg/mL of paliperidone palmitate; wherein the paliperidone palmitate extended-release injectable suspensions are aqueous compositions further comprising a suspending agent, a buffer, and optionally one or more of a preservative and an isotonizing agent, and either A) wherein the initial dose of the PP6M is administered about 1 month (± 7 days) after the last dose of the PP1M is administered, and (Ai) when the last dose of the PP1M comprises about 156 mg of paliperidone palmitate, the initial dose of the PP6M comprises about 1092 mg of paliperidone palmitate, or (Aii) when the last dose of the PP1M comprises about 234 mg of paliperidone palmitate, the initial dose of the PP6M comprises about 1560 mg of paliperidone palmitate, or B) wherein the initial dose of the PP6M is administered about 3 months (± 14 days) after the last dose of the PP3M is administered, and (Bi) when the last dose of the PP3M comprises about 546 mg of paliperidone palmitate, the initial dose of the PP6M comprises about 1092 mg of paliperidone palmitate, or (Bii) when the last dose of the PP3M comprises about 819 mg of paliperidone palmitate, the initial dose of the PP6M comprises about 1560 mg of paliperidone palmitate. A) wherein the initial dose of the PP6M is administered about 1 month (± 7 days) after the last dose of the PP1M is administered, and (Ai) when the last dose of the PP1M comprises about 156 mg of paliperidone palmitate, the initial dose of the PP6M comprises about 1092 mg of paliperidone palmitate, or (Aii) when the last dose of the PP1M comprises about 234 mg of paliperidone palmitate, the initial dose of the PP6M comprises about 1560 mg of paliperidone palmitate, or (Ai) when the last dose of the PP1M comprises about 156 mg of paliperidone palmitate, the initial dose of the PP6M comprises about 1092 mg of paliperidone palmitate, or (Aii) when the last dose of the PP1M comprises about 234 mg of paliperidone palmitate, the initial dose of the PP6M comprises about 1560 mg of paliperidone palmitate, or B) wherein the initial dose of the PP6M is administered about 3 months (± 14 days) after the last dose of the PP3M is administered, and (Bi) when the last dose of the PP3M comprises about 546 mg of paliperidone palmitate, the initial dose of the PP6M comprises about 1092 mg of paliperidone palmitate, or (Bii) when the last dose of the PP3M comprises about 819 mg of paliperidone palmitate, the initial dose of the PP6M comprises about 1560 mg of paliperidone palmitate. (Bi) when the last dose of the PP3M comprises about 546 mg of paliperidone palmitate, the initial dose of the PP6M comprises about 1092 mg of paliperidone palmitate, or (Bii) when the last dose of the PP3M comprises about 819 mg of paliperidone palmitate, the initial dose of the PP6M comprises about 1560 mg of paliperidone palmitate.